Abstract：
Chronic inflammation is a hallmark of cancer cachexia. Polyunsaturated fatty acids (ω-3 PUFAs): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are known to contribute to the reduction of inflammation, preservation of lean body mass and total body weight, and reduction of cancer-related symptoms, such as anorexia or neuropathy. This systematic review aimed to assess whether the ratio of EPA to DHA used in supplementation in cancer patients matters in the context of the resolution of inflammation and reduction of the risk of cachexia. The analysis included 20 randomized clinical trials with acceptable quality identified from the Pubmed/MEDLINE database. The significant results concerning the resolution of inflammation or improvement in nutritional status were the highest in the case of a low EPA/DHA ratio, i.e., 67%, and decreased, reaching 50% and 36% for the moderate and high ratios, respectively. Most results concerning body weight from high and moderate EPA/DHA ratios showed no benefit or were insignificant. A significant benefit in reducing any reported inflammatory markers was seen in the low EPA/DHA ratio subgroup at 63%, in the moderate at 29%, and in the high ratio subgroup at 11%. The greatest benefit in CRP reduction was obtained by patients during chemotherapy. The review questions the anticachectic and anti-inflammatory effect of ω-3 PUFAs supplementation with doses of EPA higher than DHA. A population that particularly benefits from ω-3 PUFAs supplementation are patients undergoing chemotherapy for advanced cancer.
摘要：
慢性炎症是癌症恶病质的标志。多不饱和脂肪酸（ω-3PUFA）：已知二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）有助于减少炎症，保持瘦体重和总体重，减少癌症相关症状，如厌食症或神经病。本系统评价旨在评估癌症患者中用于补充的EPA与DHA的比例在炎症消退和恶病质风险降低的背景下是否重要。分析包括从Pubmed/MEDLINE数据库中确定的20项质量可接受的随机临床试验。在低EPA/DHA比例的情况下，关于炎症消退或营养状况改善的显著结果是最高的。即，67%,减少,中高比例达到50%和36%，分别。来自高和中等EPA/DHA比率的大多数关于体重的结果显示没有益处或微不足道。在降低任何报告的炎症标志物的显著益处在低EPA/DHA比率亚组中观察到63%,在29%的中等比例中，而在高比率亚组，为11%。患者在化疗期间获得了CRP降低的最大益处。该评论质疑补充ω-3PUFA的EPA剂量高于DHA的抗病性和抗炎作用。特别受益于ω-3PUFA补充的人群是接受晚期癌症化疗的患者。
